Netherlands, Nijmegen

State of the Art Radionuclide Imaging and Therapy in Oncology

when 12 August 2019 - 16 August 2019
language English
duration 1 week
credits 2 EC
fee EUR 600

This course will update you on the latest developments on the use of radionuclides for diagnosis, treatment monitoring and therapy in oncology, covering the range from basic radiochemistry to preclinical and clinical applications.

Radionuclides are important tools for imaging and therapeutic applications in oncology. When radionuclides are combined with tumor-targeting molecules, so-called tracers, they can be used to non-invasively visualize tumor lesions. A well-known example is positron emission tomography (PET) with F]F- ftuorodeoxyglucose ([]FDG). Because of recent developments of novel biologics for therapy in oncology, more advanced radio-imaging techniques have become available. For instance, radiolabeled tracers can be used to identify patients who could benefit from the latest immunotherapies, or con be used for treatment response monitoring. ln addition to imaging, tracers can also be coupled to therapeutic radionuclides (e.g. alpha- or beta-emitters) which can be used to specifically irradiate tumor lesions while preventing exposure to healthy tissue.

Content of the course
During the course, the characteristics of different radionuclides (e.g. imaging and therapeutic radionutides) and tumor targeting agents (e.g. antibodies, peptides, small molecules) will be discussed, as well as the latest radiochemical methods to label radionuclides to targeting molecules. Furthermore, the course provides you with both knowledge and hands-on experience with cell-based assays and in vivo evolution of the tumor targeting and therapeutic efficacy of immunotherapy radiotracers. Examples are imaging of the PD-L7 checkpoint and in vivo T-cell imaging with antibodies, antibody fragments or by ex vivo cell labeling. You will learn to select the best in vitro experiment and how to set up and perform in vivo imaging and therapy experiments in several practical sessions. The final step, translation in to the clinic, will also be covered during the course, and examples will be provided of bringing imaging and therapeutic radionuclides into the clinic.

The course will contain lectures from several expert speakers, site-visits to research facilities, hands-on work with radiometals in cell assays and in vivo imaging experiments. Furthermore, we will organize meet-the-researchers sessions giving you the chance to have in-depth discussions on your topic of interest. The topics include alpha/beta-emitting therapy, immuno-oncology therapy imaging, in vivo cell tracking and radiolabeling methods.

When your oncologic research might benefit the use of radionuclides, this course will provide you with both basic knowledge and advanced insights in the exciting field of radionuclide imaging and therapy
for oncology.

Course leader

Sandra Heskamp
Assistant Professor
Radiology and nuclear medicine
Radboud UMC

Target group


The course is designed for Master students, PhD students and postdocs with a
biomedical/biochemical background. Participants should have a basic level of biomedical, biochemical and/or chemistry and physics knowledge.

Course aim

After this course you are able to:

Select the appropriate radionuclide for your application
Characterize a radiotracer with in vitro methods
Set up and perform an in vivo PET/SPECT imaging study
Set up and perform in vitro and in vivo experiments to evaluate the efficacy of therapeutic radiotracers.
Translate a preclinically validated radiotracer to the clinic

Fee info

EUR 600: Normal fee


€ 540 early bird discount – deadline 1 March 2019 (10%)
€ 510 partner + RU discount (15%)
€ 450 early bird + partner + RU discount (25%)

Register for this course
on course website